Close Menu


FIND said the funds were awarded as part of the Access to COVID-19 (ACT) Accelerator Diagnostics Pillar to accelerate testing to help mitigate the pandemic.

The collaboration will involve the evaluation of serological tests to detect the durability of patients' immune response to COVID-19.

The group is aiming to develop a fingerstick test to detect circulating levels of an antigen that is secreted continuously by living schistosomes from various species.

Over six months, Abbott and SD Biosensor will provide rapid antigen tests to a variety of countries at a maximum price of $5 per test.

FIND has convened the Access to COVID-19 Tools Accelerator Diagnostic Pillar to supply 500 million tests to countries in the next year.

News items for the in vitro diagnostics industry for the week of August 3, 2020.

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

News items for the in vitro diagnostics industry for the week of June 29, 2020.

Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.

The technology from Scanwell is also being used for its at-home SARS-CoV-2 antibody test, which is under development and awaiting Emergency Use Authorization.